Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Oct
11
Today In Oncology
ASHP Offers New Guidance for Managing IV Fluid Shortages
One Dose HPV Vaccination Approach May Help to Eliminate Cervical Cancer
Can Blood Test Predict Survival in Metastatic Prostate Cancer?
Bridging the Gap in Cancer Clinical Trial Funding
Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I NSCLC
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo